Stay up to date with the latest HIV news and research. Subscribe to aidsmap bulletins: https://www.aidsmap.com/subscribe

It's a week to go until the 6th Joint Conference of the British HIV Association (BHIVA) and the British Association for Sexual Health and HIV (BASHH) in Liverpool, UK.

aidsmap will be reporting news from the conference: https://www.aidsmap.com/conferences/bhiva-bashh-2026

Wanted: new writers for aidsmap aidsmap has long been one of the world's leading sources of accurate, independent HIV information. After a period of uncertainty, aidsmap is back – and one of our priorities is reviving Emerging Voice...

Emerging Voices gives new writers the opportunity to develop their scientific journalism skills in a professional and supportive environment.

We'd love to hear from you if you're looking to develop your scientific writing and become part of our team.

www.aidsmap.com/news/apr-202...

“They are already dead”: how outdated knowledge and cruel stereotypes contribute to depression and suicide in Malawi teens with HIV A qualitative study of adolescents living with HIV in Malawi has found that outdated beliefs about HIV, and stereotypes of people with it, contribute to pervasive and persistent stigma against young people living with the virus. This does not only have adverse psychological effects but disadvantages them in practical ways, damaging their educational and employment prospects.

“They are already dead”: how outdated knowledge and cruel stereotypes contribute to depression and suicide in Malawi teens with HIV

Tenofovir alafenamide / emtricitabine for PrEP This page provides detailed information about how to start and stop PrEP, required tests and checkups, side effects, drug interactions and drug resistance.

Tenofovir alafenamide / emtricitabine is one type of oral PrEP – a tablet taken to prevent HIV infection. Find out how to start and stop PrEP, required tests and checkups, side effects, drug interactions and drug resistance.

Cabotegravir injections for PrEP Cabotegravir is one type of long-acting PrEP – an injection taken to prevent HIV infection.

Cabotegravir is a long-acting form of PrEP, taken by injection once every 2 months. Our page provides detailed information on how to start and stop cabotegravir PrEP, required tests & check-ups, side effects, interactions and resistance.

Pre-exposure prophylaxis (PrEP) PrEP is highly effective in preventing the transmission of HIV during sex. There are several different forms of PrEP, including pills, injections and vaginal ri

PrEP (pre-exposure prophylaxis) is highly effective in preventing the transmission of HIV during sex. There are several different forms of PrEP, including pills, injections and a vaginal ring.

Tenofovir disoproxil / emtricitabine for PrEP This page provides detailed information about how to start and stop PrEP, required tests and checkups, side effects, drug interactions and drug resistance.

The most widely used type of PrEP is a tablet which contains two anti-HIV drugs, tenofovir disoproxil & emtricitabine. For PrEP to work, it needs to be taken correctly. This means having enough PrEP in your body when you need protection www.aidsmap.com/about-hiv/te...

Top 5 stories on threats to the global HIV response from CROI 2026 The withdrawal of US funding for global HIV programmes was a defining theme at the Conference on Retroviruses and Opportunistic Infections (CROI 2026) in Denver in February. Researchers and advocates grappled with both the immediate damage and the longer-term outlook. Here are five key stories from the conference.

The withdrawal of US funding for global HIV programmes was a defining theme at #CROI2026. Researchers & advocates grappled with both the immediate damage and the longer-term outlook. Here are five key stories.

Top 5 stories on HIV prevention and sexual health from CROI 2026 From a contested study on U=U to a disappointing gonorrhoea vaccine trial and the ongoing global PrEP crisis, HIV prevention was a key topic at this year's Conference on Retroviruses and Opportunistic Infections (CROI 2026) in Denver. Here are five highlights.

From a contested study on U=U to a disappointing gonorrhoea vaccine trial and the ongoing global PrEP crisis, HIV prevention was a key topic at CROI 2026 in Denver. Here are five highlights. #CROI2026

Top 5 stories on the search for an HIV cure from CROI 2026 The search for a way to control HIV without antiretroviral therapy (ART) continued to generate both promising signals and sobering setbacks at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2026) in Denver. Here are five highlights.

The search for a way to control HIV without antiretroviral therapy continued to generate both promising signals and sobering setbacks at the recent #CROI2026. Here are five highlights

Top 5 stories on the HIV response in Africa from CROI 2026 Africa is home to the majority of people living with HIV and the region hardest hit by the donor funding crisis. At this year's Conference on Retroviruses and Opportunistic Infections (CROI 2026) in Denver, there was promising science – from community-level prevention to cure research with children. Here are five highlights.

Africa is home to the majority of people living with HIV & the region hardest hit by the donor funding crisis. At #CROI2026, there was promising science – from community-level prevention to cure research with children

Top 5 stories on long-term health for people living with HIV from CROI 2026 As more people live longer with HIV, managing other health conditions is increasingly important. Research presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2026) in Denver covered a wide range of issues – from new obesity drugs and cardiovascular risk to transplant outcomes and stimulant drug use. Here are five highlights.

As more people live longer with HIV, managing other health conditions is increasingly important. Research at #CROI2026 covered a wide range of issues, including new obesity drugs and cardiovascular risk.

Top 5 stories on the future of HIV treatment from CROI 2026 The HIV treatment landscape is changing fast. Research presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2026) in Denver pointed towards a future of fewer pills, less frequent dosing and new drug classes – from twice-yearly injectables to a simplified regimen for people on complex treatment. Here are five highlights.

The HIV treatment landscape is changing fast. Research presented at #CROI2026 pointed towards a future of fewer pills, less frequent dosing and new drug classes. Here are five highlights.

The untapped potential of CD8 cells: how cellular immunity may be the key to an HIV cure Several presentations at last month’s Conference on Retroviruses and Opportunistic Infections (CROI 2026) in Denver, US provided hope for the development of therapeutic vaccinations as well as T-cell and antibody therapies that could lead to long-term control or even a cure for HIV. It had been thought that HIV infection, especially long-term infection, exhausts the immune cells that normally fight infections, leading to a state of immune ‘senescence’ (premature ageing) and long-term, low-level inflammation.

News from CROI 2026: The untapped potential of CD8 cells: how cellular immunity may be the key to an HIV cure #CROI2026

GLP-1 agonists could be a global game-changer, but need to be accessible and affordable Popular GLP-1 weight-loss medications generally work well for people living with HIV, and they may improve liver, gut and cardiovascular health and reduce smoking, along with their well-known benefits for obesity and diabetes, according to studies presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2026). However, much remains to be learned about their long-term use.

News from CROI 2026: GLP-1 agonists could be a global game-changer, but need to be accessible and affordable #CROI2026

Missed CROI this year? Catch up with the research from the conference on aidsmap.com, with our news articles, summary bulletins and video interviews. #CROI2026
https://www.aidsmap.com/conferences/croi-2026

Can someone transmit HIV with a viral load of 200? Ugandan study re-ignites the U=U debate The presentation of a study at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2026) in Denver caused consternation when it appeared to contradict data that have served as the basis for the ‘Undetectable equals Untransmittable’ (U=U) campaign, which informs people with HIV that they cannot pass on HIV during sex if they have an ‘undetectable’ viral load – defined in the foundational studies as below 200.

News from CROI 2026: Can someone transmit HIV with a viral load of 200? Ugandan study re-ignites the U=U debate #CROI2026 #UequalsU

Younger, mobile men especially likely to not know they have HIV in eastern and southern Africa One in seven men living with HIV in eastern and southern Africa are unaware that they have the virus, according to research presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2026) in Denver, US by Dr Craig Heck of Columbia University. Younger men and those who sometimes live away from home were more likely not to know their status.

News from CROI 2026: Younger, mobile men especially likely to not know they have HIV in eastern and southern Africa #CROI2026

CROI 2026: Two-drug HIV treatment doravirine / islatravir YouTube video by aidsmap

At #CROI2026, Professor Jürgen Rockstroh from the University of Bonn spoke to aidsmap.com's Roger Pebody about two-drug HIV treatment doravirine and islatravir.
www.youtube.com/watch?v=KRd_...
Find out more in our news story www.aidsmap.com/news/mar-202...

CROI 2026: HIV incidence in trans women YouTube video by aidsmap

At #CROI2026, Dr Sari Reisner from the University of Michigan spoke to aidsmap.com's Roger Pebody about HIV incidence in trans women in the United States. www.youtube.com/watch?v=3cPV...
Find out more in our news story www.aidsmap.com/news/mar-202...

Immune modulator N-803 does not control HIV rebound, suggesting a combination approach is needed for a functional cure Most people with HIV who received the immune-modulating drug N-803 (Anktiva), with or without broadly neutralising antibodies (bnAbs), did not experience delayed viral rebound after stopping antiretroviral treatment, but they did show some favourable changes in immune response and the viral reservoir, according to a set of posters presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2026) in Denver.

News from CROI 2026: Immune modulator N-803 does not control HIV rebound, suggesting a combination approach is needed for a functional cure #CROI2026

Vaccine fails to prevent gonorrhoea in Australian study A trial of a vaccine against gonorrhoea found that it was no more effective than a placebo, in a result described as “unexpected and somewhat disappointing, but very clear” when presented to the Conference on Retroviruses and Opportunistic Infections (CROI 2026) in Denver last week.

News from CROI 2026: Vaccine fails to prevent gonorrhoea in Australian study #CROI2026

New antiretrovirals in the pipeline could be part of twice-yearly HIV treatment Three experimental injectable antiretrovirals – a novel capsid inhibitor and two next-generation integrase inhibitors – could be components of future long-acting HIV treatment regimens, according to study results presented last week at the Conference on Retroviruses and Opportunistic Infections (CROI 2026) in Denver.

News from CROI 2026: New antiretrovirals in the pipeline could be part of twice-yearly HIV treatment #CROI2026

Multi-component app improves viral suppression in men who use crystal meth At the recent Conference on Retroviruses and Opportunistic Infections (CROI 2026) in Denver, US, the use of an app for men with HIV who also use illicit stimulants led to 58% lower odds of having a detectable viral load after six months, when compared to a control group who did not use the app in a fully remote randomised controlled trial.

News from CROI 2026: Multi-component app improves viral suppression in men who use crystal meth #CROI2026

CROI 2026: 4CMenB vaccine against gonorrhoea YouTube video by aidsmap

At #CROI2026, Professor Kate Seib and Professor Andrew Grulich talked to aidsmap.com's Roger Pebody about the 4CMenB vaccine against gonorrhoea. www.youtube.com/watch?v=wa-u...
Find out more in our news article: www.aidsmap.com/news/mar-202...

African paediatric studies at CROI: HIV remission in children, three bNAbs in babies, two years on injectables in teens A number of innovative approaches to treating children were presented at last week’s Conference on Retroviruses and Opportunistic Infections (CROI 2026) in Denver, US. Several were based on the fact that infants have good prospects for long-term viral suppression without antiretroviral therapy (ART). Failing that, children and adolescents, who may have particular problems with adherence to daily pills, are prime candidates for long-acting injectable formulations.

African paediatric studies at #CROI2026: HIV remission in children, three bNAbs in babies, two years on injectables in teens

On Friday, we are sending out our final summary bulletin of news from #CROI2026. Make sure you've signed up at: https://www.aidsmap.com/subscribe 
Read our second bulletin on aidsmap.com: www.aidsmap.com/bulletin/conference-news...

CROI 2026: PrEP uptake is far too low YouTube video by aidsmap

At #CROI2026, Dr Andrew Hill from the University of Liverpool spoke to aidsmap.com's @rogerpebody.bsky.social about PrEP uptake being too low globally to make a difference to the HIV epidemic. www.youtube.com/watch?v=l32X...
Find out more in our news article: www.aidsmap.com/news/feb-202...

Broadly neutralising antibody plus cabotegravir maintains viral suppression for at least a year A broadly neutralising antibody from ViiV Healthcare, now named lotivibart, could potentially be paired with cabotegravir injections for long-acting HIV treatment, according to the latest results from the EMBRACE study presented last week at the Conference on Retroviruses and Opportunistic Infections (CROI 2026) in Denver.

News from CROI 2026: Broadly neutralising antibody plus cabotegravir maintains viral suppression for at least a year #CROI2026